The National Eczema Association has published the first comprehensive national and state-level report on atopic dermatitis, giving clinicians and policymakers a condition-specific data baseline that has never existed in this form for the disease.

Until now, atopic dermatitis — one of the most common inflammatory skin conditions in both children and adults — lacked a dedicated national report that breaks down prevalence, burden, and access metrics state by state. The association frames the report as a foundational document rather than a one-off analysis.

What does the report cover?

According to the announcement, the report compiles national and state-level data on atopic dermatitis. Its core value for dermatology practice is geographic specificity:

• First-of-its-kind scope: national figures paired with individual state-level breakdowns
• Published by the National Eczema Association, the leading patient-advocacy organization for the condition
• Intended as a reference for researchers, clinicians, and policymakers working on eczema-related care and policy

Why does state-level eczema data matter?

Atopic dermatitis affects tens of millions of Americans, yet treatment access, specialist availability, and reimbursement conditions vary widely across states. A state-by-state dataset allows:

• Comparison of disease burden between states
• Identification of care gaps in regions with limited dermatology access
• Evidence to support advocacy for expanded coverage of AD therapies

For practicing dermatologists, the report offers a citable national reference when discussing population-level disease burden — useful context for patient education, grant applications, and local health-system conversations.

A first step toward standardized AD surveillance

The publication's significance lies in its precedent. No prior report has consolidated atopic dermatitis data at both national and state levels in a single comprehensive document. The National Eczema Association indicates the report is designed to serve as a baseline for future tracking of the condition across the United States.

Clinicians and researchers can expect the association to build on this framework in subsequent editions as data collection on atopic dermatitis continues to mature.